Credit: Getty Images. Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the treatment of hypertension according to US and European guidelines. Angiotensin receptor ...

A series of papers published in recent days provide reassuring data that patients taking inhibitors of the renin-angiotensin-aldosterone system (RAAS), such as ACE inhibitors and angiotensin receptor ...

Low blood pressure, or hypotension, in COVID-19 patients with a history of hypertension appears to be a risk factor for kidney damage and death. Reducing hypertension medications if and when COVID-19 ...

(UPDATED) Another observational study, in the form of a large analysis of US patients with hypertension, indicates that ACE inhibitors and ARBs are not associated with an increased risk of COVID-19 ...

DALLAS, Sept. 10, 2020 -- Reducing or eliminating high blood pressure medications if blood pressure becomes hypotensive, falling below 120/70 mm Hg, could prevent acute kidney injury and death in ...

Boston, MA - A new study shows a significant reduction in the incidence of Alzheimer's disease and dementia among subjects taking angiotensin-receptor blockers (ARBs), compared with those taking ACE ...

Angiotensin-converting–enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) are recommended widely as first-line treatments for hypertension in patients with diabetic or nondiabetic ...

Choosing the right angiotensin receptor blocker (ARB) or ARB combination can make all the difference in controlling blood pressure with minimal side effects. Recent studies show olmesartan and ...

May 5 (UPI) --Certain high blood pressure medications have been linked with more serious illness from COVID-19, but they don't increase a person's risk for getting the disease, a new study published ...

Close-up of senior black woman sorting weekly medication. Member of a black middle class America family. Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the ...

Stopping an ACE inhibitor or angiotensin receptor blocker (ARB) at admission for COVID-19 doesn't help outcomes, even for high-risk groups, the BRACE CORONA randomized trial showed. Continuing these ...